Abstract: Diabetic retinopathy (DR) occurs, to some extent, in most people with at least 20 years ' duration of diabetes mellitus. The progression of DR to its sight-threatening stages is usually associated with the worsening of underlying retinal vascular dysfunction and disease. The plasma kallikrein-kinin system (KKS) is activated during vascular injury, where it mediates important functions in innate inflammation, blood flow, and coagulation. Recent findings from human vitreous proteomics and experimental studies on diabetic animal models have implicated the KKS in contributing to DR. Vitreous fluid from people with advanced stages of DR contains increased levels of plasma KKS components, including plasma kallikrein (PK), coagulation factor XII, and high-molecular-weight kininogen. Both bradykinin B1 and B2 receptor isoforms (B1R and B2R, respectively) are expressed in human retina, and retinal B1R levels are increased in diabetic rodents. The activation of the intraocular KKS induces retinal vascular permeability, vasodilation, and retinal thickening, and these responses are exacerbated in diabetic rats. Preclinical studies have shown that the administration of PK inhibitors and B1R antagonists to diabetic rats ameliorates retinal vascular hyperpermeability and inflammation. These findings suggest that components of plasma KKS are potential therapeutic targets for diabetic macular edema.
Introduction
Diabetic retinopathy (DR) is one of the most prevalent microvascular complications of diabetes mellitus and a leading cause of vision loss in working-age adults (Mohamed et al. , 2007 ; Prokofyeva and Zrenner , 2012 ) . A recent meta-analysis of data from nearly 23,000 subjects has shown that for people with ≥ 20 years ' duration of diabetes, the prevalence of sight-threatening stages of DR including diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR) is about 20 % and 32 % , respectively, although a variety of factors can influence these rates (Yau et al. , 2012 ) . Although there has been important progress in reducing the onset of advanced stages of DR and managing the disease once it occurs (Mohamed et al. , 2007 ; Antonetti et al. , 2012 ) , there remains a tremendous clinical need for additional effective treatments for patients who are refractory or who do not fully respond to current therapeutic options. Moreover, this unmet clinical need to prevent and treat DR is projected to increase with the rise in incidence and earlier onset of diabetes (Ko et al. , 2012 ) .
Emerging clinical and experimental findings have implicated the plasma KKS in contributing to DR. Recent proteomic analysis of vitreous from people with advanced stages of DR has revealed that the vitreous fluid contains components of the KKS (Gao et al. , 2007 (Gao et al. , , 2008 ; Kim et al. , 2007 ) . Increased levels of KKS components in the retina also occur in diabetic animal models, which display increased retinal vascular responses to exogenously administered PK and des-Arg 9 -bradykinin (DABK) (Abdouh et al. , 2008 ; Clermont et al. , 2011 ) . Moreover, preclinical studies have shown that both PK inhibitors and bradykinin (BK) receptor antagonists ameliorate retinal functional abnormalities caused by diabetes (Lawson et al. , 2005 ; Abdouh et al. , 2008 ; Clermont et al. , 2011 ) . This review examines the regulation and mechanisms of KKS action in the retina and discusses potential strategies for targeting this pathway as a new therapeutic approach for treating DR.
Stages and progression of DR
DR is a chronic disease that is classified into multiple stages and involves combinations of pathophysiological processes, which can lead to retinal neovascularization, edema, and vision loss. Because it is unlikely that a single pathway or system contributes to all phases of this disease, a brief description of the pathogenesis of DR can facilitate the discussion of the stages and processes that could be most affected by the KKS system. DR is classified into multiple levels of nonproliferative diabetic retinopathy (NPDR), including mild, moderate, and severe NPDR and PDR according to the type and severity of retinal abnormalities. The earliest vascular changes in NPDR involve alterations in retinal hemodyamics, changes in retinal vessel diameters, increases in leakage across the blood-retinal barrier (BRB), and the appearance of microaneurysms, retinal hemorrhage, hard exudates, and cotton wool spots (Cheung et al. , 2010 ) . Later changes in NPDR include the worsening of these early changes and the development of intraretinal microvascular abnormalities and venous beading. Although these changes alone usually do not cause visual impairment, the progression and accumulation of this vascular injury in NPDR can cause capillary nonperfusion, leading to ischemia and hypoxia-stimulated neovascularization. This sight-threatening stage, termed PDR, involves the formation of disorganized and fragile preretinal vessels that are prone to bleed and can lead to fibrosis and tractional retinal detachment (Antonetti et al. , 2012 ) . DR can also cause intraretinal fluid accumulation and thickening of the macula, termed DME. This vision-threatening condition can occur at any stage of DR, although its prevalence is increased in patients with greater underlying diabetic retinal disease. The breakdown of BRB function in advanced stages of DR is also associated with marked alterations in the biochemical composition of intraocular fluids (Gao et al. , 2007 ; Yu et al. , 2008 ; Kim et al. , 2010 ) . The clinical characteristics of hyperpermeability, hemorrhage, ischemia, and vasogenic edema are biological processes that have been associated with the activation of the KKS in a variety of organs and diseases, including hereditary angioedema and stroke (Cicardi et al. , 2010a,b ; Liu et al. , 2010b ; Langhauser et al. , 2012 ) , suggesting areas of potential physiological interaction between the KKS and the DR.
Upregulation and activation of the KKS in DR The kallikrein-kinin system
The plasma KKS mediates important functions in blood flow, coagulation, innate inflammation, pain, and blood During the activation of the KKS system, FXII and PPK are proteolytically activated to FXIIa and PK, respectively. PK then cleaves HK to release BK, which can be subsequently cleaved to DABK. BK and DABK bind to B2R and B1R, respectively, thereby changing RVP, vasodilation, leukostasis, ERG activity, and retinal thickness. PK may also contribute to retinal hemorrhage. The activity of PK can be inhibited by C1-INH, PK inhibitor ASP-440, and neutralizing anti-PK antibody. The antagonists of B1R include des-Arg 10 -Hoe140, R-954, FOV-2304, and LF22-0542, and the antagonist of B2R is Hoe140. pressure regulation. The effects of this system are mediated by two serine protease zymogens, coagulation factor XII (FXII) and plasma prekallikrein (PPK), and its substrate, high-molecular-weight kininogen (HK) (Figure 1 ). Although the physiological mechanisms responsible for activation of the KKS are not fully understood, a key initiating step appears to involve the interactions of FXII with an activating surface, which results in the zymogen activation of FXII to factor XIIa (FXIIa) (Sainz et al. , 2007 ) . The primary substrates of FXIIa include FXI, leading to the activation of intrinsic coagulation, and PPK, resulting in the generation of PK. This proteolytically active PK can feedback to activate additional FXII and also cleave HK to liberate the nonapeptide BK. BK activates the G-proteincoupled BK 2 receptor (B2R). Subsequent cleavage of BK by carboxypeptidases generates DABK, which activates the B1 receptor (B1R). In addition to the well-established effects of PK that are mediated by HK cleavage and BK receptor activation (Joseph and Kaplan , 2005 ; Sainz et al. , 2007 ) , this serine protease has a number of other substrates that may mediate effects that are independent of BK receptors. For example, PK can proteolytically activate plasminogen (Selvarajan et al. , 2001 ) and can also directly cleave collagen and a diverse group of secreted proteins (Liu et al. , 2010b ) . Although these findings suggest that PK may have a variety of substrates, the physiological significance of many of these interactions is not yet available. Recently, we have shown that PK can also mediate effects via its collagen binding properties, which interferes with collagen-induced platelet activation and exacerbates intracerebral hematoma expansion via a BK-independent mechanism . Collectively, these data suggest that the KKS mediates its effects via both kinindependent and kinin-independent mechanisms.
KKS components in the DR vitreous
Recent proteomic analyses have identified the components of the plasma KKS, including PK, FXII, and HK in the vitreous fluid obtained from patients with advanced DR undergoing pars plana vitrectomy (Kim et al. , 2007 ; Gao et al. , 2008 ) . Moreover, vitreous HK and FXII levels detected by mass spectrometry are increased in PDR patients compared with the nondiabetic group. Immunoblot analysis has shown that a large fraction of PPK and FXII was proteolytically cleaved to active PK and FXIIa (Gao et al. , 2007 ) . Increased levels of PK and PK activity in the retina also occur in diabetic rats compared with nondiabetic controls Catanzaro et al. , 2012 ) . Consistent with plasma extravasation in DR, we also observed a 2-fold increase in C1 inhibitor (C1-INH), the primary physiological inhibitor of PK, in the vitreous from PDR subjects compared with vitreous from nondiabetic subjects (Gao et al. , 2007 ) . However, although C1-INH is detected in the vitreous, it is not known if the concentrations are sufficient to effectively inhibit the KKS.
Retinal BK receptor expression
Both B1R and B2R are expressed at high levels in the human retina, choroid, and ciliary body and at relatively low levels in the optic nerve (Ma et al. , 1996 ) . Although an in-depth analysis of BK receptor expression in retinal cell types is not yet available, these receptors are widely expressed in neuronal, glial, and vascular cell lineages. Within the retina, prominent B2R expression is observed in the ganglion cell layer, inner nuclear layer, outer nuclear layer, and vascular endothelium (Yasuyoshi et al. , 2000 ) . Diabetes has been shown to increase retinal B1R expression in rats (Abdouh et al. , 2008 ; Pouliot et al. , 2012 ) . However, the effects of diabetes and DR on retinal B1R expression in humans have not yet been reported.
Intraocular activation of KKS
Multiple mechanisms can regulate KKS activation; however, the contributions of these mechanisms to ocular KKS activity in DR are not fully understood. Increased levels of contact system components (PPK, FXII, and HK) in the eye in DR are likely the result of plasma extravasations, intraocular hemorrhage, and binding interactions that retain components in the vitreous matrix and retina. Intraocular KKS activation could occur after retinal or vitreous hemorrhage, which could increase vitreous contact system proteins along with factors that activate this system, including platelet polyphosphates, microparticles, heparin, and erythrocyte carbonic anhydrase 1 (CA-1) (Gao et al. , 2007 ; Muller et al. , 2009 ; Oschatz et al. , 2011 ; van der Meijden et al. , 2012 ) . FXII in the retina and vitreous may also become activated after interactions with extracellular matrix proteins, including collagen (van der Meijden et al. , 2009 ) and laminin (White -Adams et al., 2010 ) and misfolded or modified proteins (Maas et al. , 2008 ) . PPK activation can also involve FXII-independent mechanisms mediated by heat shock protein 90 (Joseph et al. , 2002 ) and prolylcarboxypeptidase (Shariat -Madar et al., 2002 ) . Moreover, activated PK can bind to collagen , which may retain the activated PK in the vitreous and retinal extracellular matrix. Once activated, PK ' s actions in the eye may be prolonged due to the relative deficiency of C1-INH in the vitreous compared with plasma (Kita and Feener, unpublished data) . In addition to the activation of contact system components, increased retinal B1R expression, as described in the preceding section, may also potentiate KKS actions in DR.
KKS action in DR
The physiological actions of the plasma KKS have been extensively studied both in humans and in animal models. In humans, hyperactivity of PK due to genetic C1-INH deficiency has been shown to cause vasogenic edema ( Longhurst and Cicardi , 2012 ) . Experimental studies have demonstrated that the activation of the KKS exerts a number of biological effects that also occur in DR, including increased vascular permeability and edema, changes in vascular diameter and hemodynamics, and a variety of effects on inflammation, angiogenesis, and neuronal functions. This section examines the role of the KKS in these retinal abnormalities associated with DR.
Retinal vascular permeability
The effects of the KKS on retinal vascular permeability (RVP) have been examined by intravitreal injection of active components of KKS and by local and systemic administration of PK inhibitors and BK receptor antagonists. Intraocular activation of the KKS by injection of CA-1 into the vitreous has been shown to increase RVP, and this response was inhibited by the co-injection of C1-INH, a neutralizing antibody against PK, and a smallmolecule PK inhibitor, 1-benzyl-1 H -pyrazole-4-carboxylic acid 4-carbamimidoyl-benzylamide (ASP-440) . Intravitreal injection of PK increased RVP and retinal thickness by a greater extent in diabetic rats compared with similarly treated nondiabetic rats, suggesting that diabetes enhances the retinal responses to intraocular KKS activation . Systemic administration of ASP-440 decreased RVP both in diabetic rats and in rats subjected to angiotensin II-induced hypertension (Phipps et al. , 2009 ; Clermont et al. , 2011 ) . Intravitreal injection of BK increased RVP in both diabetic and nondiabetic rats, whereas only diabetic rats demonstrated an RVP response to DABK (Abdouh et al. , 2008 ; Phipps et al. , 2009 ) . The administration of B1R antagonist reduced RVP in streptozotocin (STZ)-induced diabetic rats (Lawson et al. , 2005 ; Abdouh et al. , 2008 ) . These data suggest that the activation of the KKS in the circulation and/or locally in the retina and vitreous can increase RVP via both B1R and B2R and that diabetes appears to increase actions mediated via the B1R.
Retinal blood flow and vasodilation
The KKS can regulate retinal vessel diameters and hemodynamics. Intravitreal injection of BK acutely stimulated increases in retinal vessel diameters and blood flow in adult cats (Sogawa et al. , 2010 ) . Intravenous infusion of BK increases retinal vessel diameter in rats (Kojima et al. , 2009 ) ; however, this model also displays marked lowering of systemic blood pressure, which may contribute to its effects on retinal vessels. Ex vivo studies have shown that BK can induce dilation in vessel preparations from rat and porcine retina (Hardy et al. , 1998 ; Abdouh et al. , 2003 ) . DABK increased vessel diameters in the retinal vessels from diabetic rats but not in the retinal vessels from nondiabetic controls (Abdouh et al. , 2003 ) . Although these acute effects of BK show that the KKS can induce retinal vessel vasodilation, a 2-week systemic administration of a PK inhibitor to diabetic rats also increased retinal vessel diameters and increased retinal blood flow . The mechanisms that mediate these chronic effects of the KKS on retinal hemodynamics are unknown.
The effects of B1R and B2R on retinal vessel dilation have been mainly attributed to nitric oxide (NO) and prostaglandin (PG) generation from vascular endothelial cells (Figure 2 ) . Pouliot et al. (2012) have shown that B1R blockade reduces the retinal expression of potential inflammatory mediators, including iNOS and COX-2. In vitro , BK-induced vasodilation responses were inhibited by N G -nitro-l -arginine methyl ester, indomethacin, and the B2R antagonist Hoe140, suggesting that the vasodilation induced by BK is mediated by NO and PGs (Hardy et al. , 1998 ; Jeppesen et al. , 2002 ; Abdouh et al. , 2003 ; Dalsgaard et al. , 2010 ) . BK and DABK stimulate increases in the intracellular concentrations of free calcium by coupling G α q/11 or G α i/o through the B2R or B1R, respectively (Busse and Fleming , 1996 ; Kuhr et al. , 2010 ) . Ca 2 + -induced stimulation of phospholipase A2 (PLA2) liberated the arachidonic acid from the membrane phospholipids, which can lead to the synthesis of prostacyclin (PGI2) (Kolte et al. , 2011 ) . B2R stimulates eNOS phosphorylation via Ca 2 + -calmodulin-dependent activation, whereas under inflammatory conditions, B1R stimulation results in a much higher and prolonged NO production via G α i activation of the MAP kinase pathway, leading to the activation of iNOS (Kuhr et al. , 2010 ; Brovkovych et al. , 2011 ) . The activation of eNOS and iNOS can independently and additively increase NO production (Yayama and Okamoto , 2008 ; Kuhr et al. , 2010 ) . BK also activates the Src kinases and the subsequent vascular endothelial cadherin (VEC) phosphorylation, leading to the quick and reversible opening of endothelial cell junctions and plasma leakage (Orsenigo et al. , 2012 ) . NO and PGI2 activates the downstream sig naling cascade in vascular smooth muscle cells to produce vasodilatation (Giles et al. , 2012 ) .
Inflammation and angiogenesis
The recruitment of inflammatory cells to the retina and the local release of proinflammatory cytokines have been implicated in contributing to the pathogenesis of DR (Joussen et al. , 2004 ; Huang et al. , 2011 ) . Although increased retinal inflammation alone is not sufficient to cause DR, the additive effects of inflammation on vascular permeability, capillary degeneration, reactive oxygen species production, and cytokine actions on the metabolic effects of diabetes may accelerate or worsen DR progression (Talahalli et al. , 2012 ) . The proinflammatory effects of the KKS on the retina have been primarily attributed to the B1R, which is increased in the diabetic retina (Abdouh et al. , 2008 ; Pouliot et al. , 2012 ) . Although the effects of B1R activation on the retina are not fully understood, B1R activation has been shown to mediate a host of inflammatory effects in other systems, including the recruitment and activation of neutrophils and microglia (Ehrenfeld et al. , 2006 ; Ifuku et al. , 2007 ) . Pouliot et al. (2012) have reported that B1R antagonism reduced retinal leukostasis and levels of inflammatory mediators including iNOS, COX-2, and IL-1 β in diabetic rats. Interestingly, this report also showed that B1R blockade reduced the retinal B1R levels, suggesting the B1R mediates positive feedback of its expression.
The development of capillary degeneration and closure in the retina can lead to areas of nonperfusion, resulting in hypoxia-induced neovascularization. Although the role of the KKS in the ischemic retina is not yet available, both PK and B1R have been implicated in contributing to ischemic injury of other tissues, including the brain (Storini et al. , 2006 ; Austinat et al. , 2009 ) . A recent study has reported that tissue kallikrein could inhibit retinal neovascularization in mice via the cleavage of VEGF165 (Nakamura et al. , 2011 ) ; however, the potential effects of the plasma KKS on retinal new vessel growth are still unknown. In other systems, both proangiogenic and anti-angiogenic effects of plasma KKS components have been described (Parenti et al. , 2001 ; Guo and Colman , 2005 ; Krankel et al. , 2008 ) . Although the KKS could potentially influence both the ischemic injury leading to retinal neovascularization and processes contributing new vessel growth via multiple mechanisms in PDR, additional information in these areas is needed. 
Neuroretinal functions
Diabetes can cause retinal neurodegeneration, which mainly involves the inner retinal layers including the ganglion cell layer (van Dijk et al. , 2012 ; Yang et al. , 2012 ) . The effects of diabetes on retinal function has been demonstrated using electroretinography (ERG), which measures the responses of photoreceptors (a-wave) to incident light stimulation followed by the combined responses of bipolar, amacrine, ganglion, and M ü ller cells b-wave. ERG studies in patients with diabetes have indicated inner retinal neural impairment (Lecleire -Collet et al., 2011 ) . In a normal cat retina, ERG studies have suggested that BK influences inner retinal function by affecting the b-wave implicit time without affecting its amplitude (Jacobi et al. , 1996 ) .
BK has been shown to mediate a variety of activities within the neuronal tissues, including the stimulation of the glutamate release from astrocytes and the modulation of the activities of the sensory ion channels (Parpura et al. , 1994 ; Mizumura et al. , 2009 ; Liu et al. , 2010a ) . In addition, both B1R and B2R activation can regulate glutamate clearance by retinal pigmented epithelial cells through a PKC-Akt-COX-2 signaling cascade (Lim et al. , 2009 ). The potential effects of intraocular activation of the KKS on the neuroretina are largely unknown. The analysis of BK receptor expression in the neuroretina has indicated B1R expression in the ganglion cell layer, outer nuclear layer, and inner nuclear layer (Ma et al. , 1996 ; Takeda et al. , 1999 ) . In vitro , BK has also been shown to have protective effects on cultured rat retinal neurons from glutamate cytotoxicity via B2R by opening the mitochondrial adenosine triphosphate (ATP)-sensitive potassium channel (Yasuyoshi et al. , 2000 ; Yamauchi et al. , 2003 ) . Since BK is a potent neuropeptide, it is possible that the activation of the intraocular KKS may contribute to neuroretinal dysfunction in DR.
KKS inhibitors: novel therapeutic applications to DR
Diabetes is associated with both intraocular and systemic contact system activation. In addition to increases in the intraocular KKS in DR as described above, diabetes can also have systemic effects on the contact activation system. Increased fasting glucose and glycosylated hemoglobin A1c correlates with a shortened activated partial thromboplastin time (APTT), which measures the intrinsic and common coagulation cascades, including the contact system (Lippi et al. , 2009 ; Zhao et al. , 2011 ) . The shortened APTT in patients with DR also correlates with increased PPK (Kedzierska et al. , 2005 ) . In both humans and animal models, the genetic deficiency of PPK causes the prolongation of the APTT without causing an apparent prothrombotic phenotype or bleeding diathesis (Girolami et al. , 2010 ; Bird et al. , 2012 ) . In experimental studies, APTT is shortened in STZ-induced diabetic rats, and this decrease is reversed by the systemic administration of a PK inhibitor . These results suggest that systemic PK activity contributes to APTT shortening in diabetes. Because increased activities of PK and BK receptors have been linked to vasogenic edema (Plesnila et al. , 2001 ) , which is the primary cause of DME, inhibitors of the KKS may provide therapeutic opportunities for this disease. Targeting the KKS could occur at multiple levels, including the inhibition of contact system activation, selective inhibition of PK activity, and blockade of BK receptors.
Inhibiting contact system activation
Decreasing the contact system activation may provide opportunities to reduce the effects of the KKS in DR. In our previous studies, we found that CA-1 is increased in the vitreous in PDR patients and intravitreal injection of CA-1 into rats increases RVP, and this response is blocked by co-injection with CA inhibitors, a PK-neutralizing antibody, BK receptor antagonists, and a small-molecule PK inhibitor (Gao et al. , 2007 ; Clermont et al. , 2011 ) . These findings revealed that increased CA activity in the vitreous leads to KKS activation and suggest that CA-1 inhibitors may reduce DME, in part, via the reduction of the PK activity. Further elucidation of the mechanisms that contribute to intraocular KKS activation, including factors that activate FXII (described in the Intraocular Activation of KKS section), may suggest additional opportunities to regulate this pathway.
Plasma kallikrein inhibitors
PK inhibitors include endogenous inhibitors, engineered proteins, and small molecules. C1-INH is a primary physiological inhibitor of PK, FXIa, FXIIa, C1r, and C1s proteases. Both plasma-derived and recombinant forms of C1-INH are effective treatments for hereditary angioedema ( Longhurst and Cicardi , 2012 ) . We have shown that intravitreal injection of exogenous C1-INH reduced retinal vascular hyperpermeability induced by diabetes and by intravitreal CA-1 in rats (Gao et al. , 2007 ; Clermont et al. , 2011 ) . Although C1-INH is detected in the vitreous, it is unknown whether intravitreal concentrations of this endogenous serpin protease inhibitor are sufficient to inhibit PK. Exogenously administered C1-INH into the vitreous may provide an opportunity to inhibit the KKS, as well as other proteases in the complement and intrinsic coagulation cascades.
Selective PK inhibition could provide increased efficacy and targeting of the inflammatory effects of the plasma KKS while preserving the potential beneficial effects of the tissue kallikrein system. Previous studies have also shown that intravitreal injection of a PK-neutralizing antibody in rats reduced CA-1-stimulated RVP (Gao et al. , 2007 ) . The administration of the small-molecule selective PK inhibitor, ASP-440, in diabetic rats normalized both RVP and retinal blood flow . This small-molecule inhibitor also reduced RVP induced by intravitreal CA-1 injection and by angiotensin II-induced hypertension but did not affect the VEGFstimulated RVP (Phipps et al. , 2009 ; Clermont et al. , 2011 ) . These reports suggest that both systemic and intravitreal administration of PK inhibitors are effective in reducing retinal vascular hyperpermeability in diabetes.
B1 receptor antagonists
The effects of the KKS are mediated in large part via the generation of BK peptides that activate B1 and B2 receptors, which are expressed in a variety of ocular cell types and tissues. Because both PK-and tissue kallikreinmediated pathways activate BK receptors, the antagonism of these receptors blocks the effects of both kallikrein systems. Although both B1 and B2 receptors can induce RVP, B1R appears to mediate a greater effect on increased plasma extravasations in DR. The effects of several B1R antagonists on retinal vascular dysfunction in rodent models of diabetes have been described. The selective peptide B1R antagonist, R-954, reduced vascular permeability in a variety of tissues from STZ-induced diabetic rats, including the retina (Lawson et al. , 2005 ) . When STZ-induced diabetic rats were treated with R-954 for 5 days at the end of the 4-and 12-week periods of diabetes onset, NO, kallikrein activity, and capillary permeability were remarkably reduced and the Na + /K + ATPase activity in the retina was increased (Catanzaro et al. , 2012 ) . Treatment of diabetic rats with FOV-2304, a nonpeptide B1R antagonist administered via an eye drop formulation, reduced RVP, leukocyte adhesion, and normalized retinal mRNA expression of inflammatory mediators (Pruneau et al. , 2010 ) . Pouliot et al. (2012) have reported that retinal plasma extravasation, leukostasis, and RVP were significantly increased in the diabetic retina compared with control rats, and these abnormalities were reversed to control levels when treated with one eye drop of the nonpeptide B1R antagonist LF22-0542 twice a day for 7 days. These reports indicate that both local and systemic administrations of B1R antagonists are effective in ameliorating retinal vascular abnormalities in diabetic rodents, which are similar to the findings observed using PK inhibitors.
Conclusion
A growing body of evidence has implicated the KKS in contributing to the development of DR. Recent studies have revealed that the KKS is increased in the vitreous of people with advanced DR and that retinal B1R expression is increased in diabetic rodents. Activation of the KKS may contribute to the pathogenesis of DR by increasing RVP, leukostasis, retina hemorrhage, and retinal thickening and by altering retina blood flow and ERG responses. In experimental animal models, both systemic and local ocular delivery of PK inhibitors and B1R antagonists ameliorate the retinal functional abnormalities caused by diabetes. Taken together, these findings suggest that inhibition of the plasma KKS may provide new opportunities for the treatment of DR, especially DME.
